Comparison of the efficacy and safety of intralesional triamcinolone injection versus fractional CO2 laser therapy in the treatment of scars

Comparison of the efficacy and safety of intralesional triamcinolone injection versus fractional CO2 laser therapy in the treatment of second- and third-degree burn scars in individuals over 7 years of age

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250930067432N1

Enrollment

Registered

2025-10-10

Start date

2025-10-22

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burn scars. L91.8Other hypertrophic disorders of skin

Interventions

Intervention 1: Intervention Group:Triamcinolone Group: Intralesional injection of triamcinolone acetonide (40 mg/mL) administered every 4 to 6 weeks, for a maximum of 6 sessions, using local anesthes

Eligibility

Sex/Gender

All

Age

7 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age range: 7 to 60 years Hypertrophic or keloid scar Absence of uncontrolled systemic diseases

Exclusion criteria

Exclusion criteria: Pregnancy History of allergy to corticosteroids Active infection at the site of the scar

Design outcomes

Primary

Measure	Time frame
Outcomes are assessed at baseline, after each treatment session, and three months following the completion of therapy. The primary criteria include scar thickness, scar pliability (evaluated by appropriate methods), clinical symptoms (pain, itching, and erythema assessed using the Vancouver Scar Scale), and quality of life (measured by the Dermatology Life Quality Index [DLQI] questionnaire).Side effects such as skin atrophy, telangiectasia, pigmentary changes, and persistent erythema are also recorded.To compare the effectiveness of two burn scar treatment methods—triamcinolone acetonide (TAC) injection and fractional CO2 laser therapy—two validated and practical tools can be used:- The Vancouver Scar Scale (VSS) to assess physical and visual changes in the scar- The Dermatology Life Quality Index (DLQI) to evaluate the impact of the scar on daily life and the patient’s emotional well-being. Timepoint: The outcomes are evaluated at baseline, after each treatment session, and three months following the completion of therapy. Method of measurement: The main criteria include scar thickness, scar pliability (assessed by appropriate methods), clinical symptoms (pain, itching, and erythema evaluated using the Vancouver Scar Scale), and quality of life (measured by the Dermatology Life Quality Index questionnaire.	—

Measure

Time frame

Outcomes are assessed at baseline, after each treatment session, and three months following the completion of therapy. The primary criteria include scar thickness, scar pliability (evaluated by appropriate methods), clinical symptoms (pain, itching, and erythema assessed using the Vancouver Scar Scale), and quality of life (measured by the Dermatology Life Quality Index [DLQI] questionnaire).Side effects such as skin atrophy, telangiectasia, pigmentary changes, and persistent erythema are also recorded.To compare the effectiveness of two burn scar treatment methods—triamcinolone acetonide (TAC) injection and fractional CO2 laser therapy—two validated and practical tools can be used:- The Vancouver Scar Scale (VSS) to assess physical and visual changes in the scar- The Dermatology Life Quality Index (DLQI) to evaluate the impact of the scar on daily life and the patient’s emotional well-being. Timepoint: The outcomes are evaluated at baseline, after each treatment session, and three months following the completion of therapy. Method of measurement: The main criteria include scar thickness, scar pliability (assessed by appropriate methods), clinical symptoms (pain, itching, and erythema evaluated using the Vancouver Scar Scale), and quality of life (measured by the Dermatology Life Quality Index questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Abbas Ghaheri

Ahvaz University of Medical Sciences

Ghaheri.a@jamus.ac.ir+98 61 3554 7992

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026